Why It Matters

EMD Millipore faces a critical threat from reciprocal tariffs on pharmaceutical inputs that could disrupt supply chains and increase manufacturing costs. The company is lobbying against Executive Order 14257, which targets reciprocal tariffs to address trade deficits. Legislative solutions include carving out exemptions for life sciences manufacturers or establishing "Trusted Trade Partner Agreements" that eliminate duties on medical goods with allied nations—an approach championed by the bipartisan Medical Supply Chain Resiliency Act (S.998 / H.R.2213).

By the Numbers

EMD Millipore Corp. spent $90,000 on in-house lobbying in this quarter, focusing exclusively on Executive Order 14257’s manufacturing impacts. The company has spent $1.62 million in total lobbying expenditures since 2020, shifting substantially in-house in late 2022 with 14 disclosures totaling $840,000 since then.

Previous external relationships included Tiber Creek Group Inc. ($520,000, 2020-2022), Todd Strategy Group ($170,000, 2024-2025), and Covington & Burling LLP ($90,000, 2021).

Andrew Michael Tantillo, the sole registered in-house lobbyist, brings 12 years of House experience, including roles as D.C. Chief of Staff for Rep. Brian Higgins (D-NY) and Legislative Assistant to former House Appropriations Committee chairman Dave Obey (D-WI).

The Agenda

EMD Millipore is lobbying specifically on Executive Order 14257, which implements reciprocal tariffs to address U.S. trade deficits. This effort fits a broader industry pattern—PhRMA has repeatedly lobbied on pharmaceutical tariff actions in 2025. EMD Millipore’s Q2 2025 filing addressed the same executive order, indicating a persistent advocacy campaign.

Congress is actively debating alternatives. The Medical Supply Chain Resiliency Act would negotiate "Trusted Trade Partner Agreements" to eliminate duties on medical goods with allies. Member sentiment is divided: Senator Rick Scott backs Section 232 tariffs on generic medicines, while Senator Jeanne Shaheen warned that 25% pharmaceutical tariffs would spike prices.

Broader Context

The Trump administration has pursued aggressive tariff strategies, including Executive Order 14257 on reciprocal tariffs and threats of 100% tariffs on branded pharmaceuticals. However, the administration has begun negotiating individual exemptions with manufacturers.

The policy reflects national security concerns—China supplies roughly 40% of critical pharmaceutical inputs and maintains near-monopolies on essential medicines. Yet policy analysts warn that broad tariffs could increase medication costs by approximately $600 per household annually.

Between The Lines

The House Ways and Means Committee and Senate Finance Committee held hearings on the President’s 2025 Trade Policy Agenda, with reciprocal tariffs dominating discussions.

Multiple bipartisan bills offer alternatives. The ABC Safe Drug Act (S.1407) would restrict federal programs from purchasing drugs manufactured in China. The MAPS Act (H.R.4191) focuses on mapping supply chain vulnerabilities.

A bipartisan group including Rep. Nicole Malliotakis (R-NY) and Sen. Chris Coons (D-DE) championed the Medical Supply Chain Resiliency Act. House Republicans formed the American-Made Medicines Caucus to promote onshoring policies.

Competitive Landscape

EMD Millipore’s lobbying occurs within a coordinated industry effort. PhRMA has emerged as the primary industry voice, filing comprehensive reports throughout 2025 prioritizing "trade policies and administrative tariff actions" affecting pharmaceutical ingredient sourcing.

This reflects industry alignment that reciprocal tariffs could disrupt supply chains and increase costs, despite policy goals of reshoring production. The advocacy operates alongside competing congressional voices, with some lawmakers supporting tariffs while others raise price concerns.

The Bottom Line

EMD Millipore Corp. spent $90,000 lobbying against potential tariffs on pharmaceutical manufacturing inputs, targeting Executive Order 14257 on reciprocal tariffs. The company’s efforts align with broader industry push back concerned that tariffs could disrupt supply chains and increase costs. The lobbying comes as Congress debates alternatives, including the bipartisan Medical Supply Chain Resiliency Act that would use trade partnerships instead of tariffs to secure pharmaceutical supplies.

For more detailed insights access Legis1. Request a demo today!

Spot something wrong? Report an issue with this article